A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

NCT01905592 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

216

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to futility.

Conditions

Neoplasms, Breast
Carcinoma of Breast
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
BRCA1 Gene Mutation
BRCA2 Gene Mutation
Ovarian Neoplasms

Interventions

DRUG: niraparib
DRUG: Physician's choice

Sponsor

Tesaro, Inc.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]